Eli Lilly and Company $LLY is Twin Capital Management Inc.’s 10th Largest Position

Twin Capital Management Inc. lowered its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 18.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 15,761 shares of the company’s stock after selling 3,615 shares during the quarter. Eli Lilly and Company makes up 1.5% of Twin Capital Management Inc.’s holdings, making the stock its 10th largest position. Twin Capital Management Inc.’s holdings in Eli Lilly and Company were worth $12,026,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of LLY. Appleton Partners Inc. MA raised its stake in shares of Eli Lilly and Company by 293.6% during the 3rd quarter. Appleton Partners Inc. MA now owns 18,204 shares of the company’s stock worth $13,890,000 after buying an additional 13,579 shares during the period. Wellington Shields Capital Management LLC increased its holdings in Eli Lilly and Company by 13.3% in the 3rd quarter. Wellington Shields Capital Management LLC now owns 5,871 shares of the company’s stock worth $4,480,000 after acquiring an additional 687 shares in the last quarter. Birmingham Capital Management Co. Inc. AL increased its holdings in Eli Lilly and Company by 15.5% in the 3rd quarter. Birmingham Capital Management Co. Inc. AL now owns 11,930 shares of the company’s stock worth $9,103,000 after acquiring an additional 1,600 shares in the last quarter. Greater Midwest Financial Group LLC raised its position in Eli Lilly and Company by 1.9% during the third quarter. Greater Midwest Financial Group LLC now owns 1,380 shares of the company’s stock worth $1,053,000 after acquiring an additional 26 shares during the period. Finally, State of Michigan Retirement System lifted its holdings in Eli Lilly and Company by 0.4% during the third quarter. State of Michigan Retirement System now owns 266,604 shares of the company’s stock valued at $203,419,000 after purchasing an additional 1,100 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have recently commented on LLY shares. Loop Capital set a $950.00 target price on shares of Eli Lilly and Company in a research note on Monday, November 10th. Leerink Partners set a $1,234.00 target price on Eli Lilly and Company in a report on Monday, January 5th. Guggenheim decreased their target price on Eli Lilly and Company from $1,163.00 to $1,161.00 and set a “buy” rating on the stock in a research report on Tuesday, January 20th. Scotiabank reiterated an “outperform” rating and set a $1,300.00 price target on shares of Eli Lilly and Company in a research report on Thursday. Finally, Jefferies Financial Group increased their price objective on Eli Lilly and Company from $976.00 to $1,300.00 and gave the company a “buy” rating in a research note on Thursday, January 8th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average target price of $1,201.17.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock opened at $1,057.10 on Friday. The business’s 50 day moving average price is $1,052.25 and its 200 day moving average price is $898.21. The company has a market cap of $999.36 billion, a price-to-earnings ratio of 46.06, a PEG ratio of 0.74 and a beta of 0.39. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.24 and a current ratio of 1.55. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $7.48 by $0.06. The business had revenue of $19.29 billion during the quarter, compared to the consensus estimate of $17.85 billion. Eli Lilly and Company had a return on equity of 112.50% and a net margin of 31.66%.The company’s revenue for the quarter was up 42.6% on a year-over-year basis. During the same period last year, the company earned $5.32 EPS. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be paid a $1.73 dividend. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date of this dividend is Friday, February 13th. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. Eli Lilly and Company’s dividend payout ratio is currently 29.35%.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q4 beat and stunning 2026 guidance — Lilly reported strong Q4 revenue and EPS and issued 2026 guidance well above Street expectations, which sparked the initial rally as investors priced in sustained GLP‑1 growth and margin leverage. Eli Lilly Booms, Then Busts: Stellar Guidance vs Hims Undercut
• Positive Sentiment: Analysts raising price targets — Multiple banks (JPMorgan, Morgan Stanley, Cantor Fitzgerald) lifted LLY price targets and kept overweight/positive views after the results, supporting upside expectations. Price Target Raised to $1,300.00 at JPMorgan Chase & Co. Price Target Raised to $1,313.00 at Morgan Stanley Price Target Raised to $1,205.00 at Cantor Fitzgerald
• Positive Sentiment: Manufacturing and capacity expansion — Lilly is expanding GLP‑1 capacity and building greenfield sites to meet volume demand, which investors view as a durable competitive advantage versus peers constrained by supply. Eli Lilly Expands GLP-1 Capacity While Building Beyond Obesity And Diabetes
• Neutral Sentiment: Obesity market size and longer‑term thesis — Coverage highlights a very large addressable market (approaching ~$100B for obesity drugs), reinforcing the long‑term growth story even as short‑term skirmishes play out. Eli Lilly vs Novo Nordisk: The 1 Figure Investors Shouldn’t Ignore
• Neutral Sentiment: Fund/score coverage — Research pieces (Zacks, institutional letters) reinforce Lilly’s growth ranking and investor interest, but are confirmatory rather than catalytic. Eli Lilly (LLY) is a Top-Ranked Growth Stock: Should You Buy?
• Negative Sentiment: Competitive pricing pressure from compounded copies — Hims & Hers launching low‑cost compounded semaglutide pills ($49 introductory) triggered a selloff as investors feared erosion of pricing/patient share for branded oral options. This remains the main short‑term risk to LLY’s oral launch economics. Novo Nordisk and Eli Lilly fall after Hims & Hers announce $49 copy of Wegovy pill
• Negative Sentiment: Regulatory/legal noise — Separately, securities‑law firms have flagged investigations into certain transactions and board conduct; these are reputational/legal items to monitor but not yet material to the core GLP‑1 thesis. Investor Alert: Scott+Scott Investigates Directors and Officers

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.